#Pmx models of antibodies nonmem series
In this work, we model the relationship between immunogenicity and protective efficacy of a series of Ad26 vectors encoding stabilized variants of the SARS-CoV-2 Spike protein in rhesus macaques and validate the analyses by challenging macaques 6 months after immunization with the vaccine candidate that has been selected for clinical development. Data on other coronaviruses after natural infection suggest that immunity to SARS-CoV-2 might be short-lived, and preliminary evidence indicates waning antibody titers following SARS-CoV-2 infection. Limited knowledge on duration of immunity and efficacy of these vaccines is currently available. Several COVID-19 vaccines have recently gained authorization for emergency use. Nature Communications volume 12, Article number: 5877 ( 2021) SARS-CoV-2 binding and neutralizing antibody levels after vaccination predict durable protection in rhesus macaques